The continued rally in the S&P 500 in June again validated the buy-the-dip strategy. Are there any compelling investment ideas out there that may have flown under your radar?
Below is a list of June Buy recommendations made by analysts who had no other bullish recommendations over the past 3 months.
For your directory assistance, we’ve classified the opportunities by sector.
Healthcare
Context Therapeutics (CNTX) – Longtime analyst Debra Fiakas says it is well-capitalized and trades at a deep discount to book value, while positive clinical data could trigger a significant re-rating and share price upside. – Context Therapeutics: Undervalued Cancer Fighter
Spero Therapeutics (SPRO) – Biotech Fan, who focuses on biotech, highlights a catalyst — based on the positive results of the Phase 3 study, Tebipenem is expected to be approved under the SPA in mid-2026, and approval is expected to trigger in total $175 million in milestone payments over the next 12 months. – Spero Therapeutics — Additional Upside Potential Following Positive Phase 3 Results
LifeMD (LFMD) – Dragon Rock Capital, who has experience as an equities trader at a bulge-bracket investment bank, says it is a fast-growing, profitable telehealth company with strong partnerships, a robust tech stack, and a valuable SaaS asset. – LifeMD: Inflection Into Profitability Should Drive Stock Upward
Xeris Biopharma (XERS) – Bondy Investing, who focuses on mid-caps, notes that it has successfully launched products that are already generating revenue, and revenue is expected to grow significantly by 2030, while XP-8121 may serve as a catalyst for a higher valuation. – Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Niagen Bioscience (NAGE) – Longtime analyst Adestella Investment Management says it is a leader in the growing NAD+ supplement market, benefiting from rising health and longevity trends, while analyst estimates for 2025
Read the full article here